On 23 April 2020 the first 12 study subjects are vaccinated with the BioNTech mRNA vaccine candidate after Germany regulator approves Phase I/II clinical trial. [1]
On 23 April 2020 the first 12 study subjects are vaccinated with the BioNTech mRNA vaccine candidate after Germany regulator approves Phase I/II clinical trial. [1]